Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors-Reference-Cited by-同舟云学术

Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors

Published:2015-01 Issue:1 Volume:39 Page:58-64
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Lipton J.H.,Bryden P.,Sidhu M.K.,Huang H.,McGarry L.J.,Lustgarten S.,Mealing S.,Woods B.,Whelan J.,Hawkins N.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference33 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013

2. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib;Hochhaus;Leukemia,2008

3. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R);Kantarjian;Cancer,2009

4. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results;Kantarjian;Blood,2011

5. Pfizer Bosulif Prescribing Information, Sep 2013. 2013.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring;American Journal of Hematology;2024-08-02

2. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

3. Ponatinib‐review of historical development, current status, and future research;American Journal of Hematology;2024-05-10

4. Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registry;2024-03-21

5. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance;Leukemia;2024-02-29